Race Oncology Ltd has released a press release.
Zantrene highly effective in EMD AML Mouse Model
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Oncology: ASX Small and Mid-Cap Conference Presentation
- Compelling Zantrene Preclinical Kidney Cancer Data
- Race Oncology: Application for quotation of securities - RAC
- MD Anderson Preclinical AML Study on Zantrene Published
- Race raises $29.7 million in oversubscribed SPP
Later from Racura Oncology
- Supply Agreement for EMD AML Trial
- Race receives Human Ethics AML Trial Approval
- Race Receives Governance Approval for AML EMD & MDS Trial
- Zantrene AML trial in Israel advances to Phase 2
- EMD AML MDS Trial Expands to Europe
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology